Proactive Investors - Run By Investors For Investors

Callitas Health promotes Joshua Maurice to sales VP

Maurice’s promotion comes as the clinical-stage pharmaceutical development group advances its programs and partnerships
desk
Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery and other proprietary drugs

Callitas Health Inc (CSE:LILY) (OTCQB:MPHMF) said Tuesday that Joshua Maurice has been promoted to vice-president of sales and business development.

Maurice’s promotion comes as the clinical-stage pharmaceutical development group adds to its management and hires consultants to advance its programs and partnerships and build on this year’s progress.

READ: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs

“We’ve seen important strides in the first months of 2019 across the women’s health, cannabinoid and infertility spaces and deepening partnerships with companies like NFI Consumer Healthcare and Lifestyles,” said James Thompson, CEO of Callitas, in a statement.

“Promoting Joshua to this new position allows us to utilize his talents to further capitalize on these advancements in the company,” he added.

Formed in early 2015, Callitas Health is developing innovative remedies for weight management, female sexual health, cannabis delivery technologies and other proprietary drugs.

Callitas shares slipped a cent to hit $0.10 in New York trade on Tuesday morning.

Contact Ellen Kelleher at [email protected]

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use